Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Cancer Research Campaign yesterday launched an appeal for 20,000 women to take part in "probably the most ambitious cancer trial ever undertaken", writes Liz Hunt.
Women with breast cancer are needed for a four-year study of the drug tamoxifen, a successful preventive treatment for the disease, which is believed to be responsible for the recent fall in the death rate. Up to half a million women in the United Kingdom already take the drug, but the new trial will focus on the benefits - or otherwise - of long-term treatment. Tamoxifen has been used since the mid-1960s, but was only confirmed as a useful preventative treatment for breast cancer in 1990.
The trial is being funded by the United Kingdom Co-ordinating Committee for Cancer Research, comprising the CRC, Imperial Cancer Research Fund and the Medical Research Council. It will run in parallel with another tamoxifen trial which began recruiting volunteers earlier this yea, and aims to see if the drug can prevent breast cancer in healthy women with a family history of the disease. This earlier trial ran into ethical problems because of the risks of giving healthy women such a potent hormonal drug. The MRC has twice refused to back it but is believed to be reconsidering its position.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments